BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor α chimeric protein (PMLRARα) to block neutrophil differentiation and initiate acute leukemia

Journal of Experimental Medicine

Volumn 193, Issue 4, 2001, Pages 531-543

  Kogan, Scott C ^a,f   Brown, Diane E ^b   Shultz, David B ^a   Truong, Bao Tran H ^a   Lallemand Breitenbach, Valerie ^c   Guillemin, Marie Claude ^c   Lagasse, Eric ^d   Weissman, Irving L ^e   Bishop, J Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ST LOUIS CHILDREN S HOSPITAL   (United States)

^c SAINT LOUIS HOSPITAL   (France)

^d StemCells   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute leukopoiesis PML protein receptors; Leukemia; Myeloid leukemia; Promyelocytic; Retinoic acid

Indexed keywords

PROTEIN BCL 2; RETINOIC ACID RECEPTOR;

ACUTE LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CHROMOSOME 10; CHROMOSOME 15; CHROMOSOME 7; CHROMOSOME 8; CONTROLLED STUDY; FEMALE; LEUKEMOGENESIS; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, DIFFERENTIATION; APOPTOSIS; BONE MARROW CELLS; CALCIUM-BINDING PROTEINS; CALGRANULIN A; CELL DIFFERENTIATION; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; HEMATOPOIETIC STEM CELLS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOPOIESIS; MICE; MICE, TRANSGENIC; MYELOID CELLS; NEOPLASM PROTEINS; NEUTROPHILS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT FUSION PROTEINS;

EID: 0035910748     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.193.4.531     Document Type: Article

References (55)

1. The molecular basis of leukemia
2. Oncogenic transcription factors in the human acute leukemias
3. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
4. A PML-RARα transgene initiates murine acute promyelocytic leukemia
5. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARα under control of cathepsin G regulatory sequences
6. Acute leukemia with promyelocytic features in PML/RARα transgenic mice
7. The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells
8. The PML-RARα gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells
9. Promyelocytic leukemia-specific PML-retinoic acid α receptor fusion protein interferes with erythroid differentiation of human erythroleukemia K562 cells
10. Terminal megakaryocytic differentiation of TF-1 cells is induced by phorbol esters and thrombopoietin and is blocked by expression of PML/RARα fusion protein
11. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RARα mutation
12. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARα fusion protein
13. Leukemia initiated by PMLRARα: The PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable
14. Cell death induction by the acute promyelocytic leukemia-specific PML/RARα fusion protein
15. PML/RARα, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells
16. PML is essential for multiple apoptotic pathways
17. PML/RARα fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype
18. BCL-2 family members and the mitochondria in apoptosis
19. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia
20. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy
21. Bcl-2 oncoprotein expression in acute myeloid leukemia
22. Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia
23. Multiparameter flow-cytometric analysis of bcl-2 and Fas expression in normal and neoplastic hematopoiesis
24. Differential expression of BCL-2 oncoprotein and Fas antigen on normal peripheral blood and leukemic bone marrow cells. A flow cytometric analysis
25. Clinical and laboratory evaluation of all-trans retinoic acid modulation of chemotherapy in patients with acute myelogenous leukaemia
26. Bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages
27. The PEBP2βMYH11 fusion created by Inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia
28. A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry
29. Detection of multiple gains and losses of genetic material in ten glioma cell lines by comparative genomic hybridization
30. Targeted expression of MYCN causes neuroblastoma in transgenic mice
31. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia
32. p53-dependent apoptosis suppresses tumor growth and progression in vivo
33. Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice
34. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia
35. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines
36. Cytogenetic studies in acute promyelocytic leukemia: A survey of secondary chromosomal abnormalities
37. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): A report on 50 patients
38. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia
39. Secondary cytogenetic changes in acute promyelocytic leukemia - Prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: A cancer and leukemia group B study
40. An E mu-BCL-2 transgene facilitates leukaemogenesis by ionizing radiation
41. Molecular mapping of chromosome 2 deletions in murine radiation-induced AML localizes a putative tumor suppressor gene to a 1.0 cM region homologous to human chromosome segment 11p11-12
42. Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice
43. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis
44. Dysregulated bcl-2 expression inhibits apoptosis but not differentiation of retinoic acid-induced HL-60 granulocytes
45. Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2
46. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival
47. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics
48. Role of promyelocytic leukemia (PML) in tumor suppression
49. A bcr-3 isoform of RARα-PML potentiates the development of PML-RARα-driven acute promyelocytic leukemia
50. The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation
51. Modulation of p53, WAF1/p21 and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells
52. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins
53. 3 exerts dose-dependent dual effects on APL cells
54. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide